Analysis updated on Nov. 9, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI scores Spyre Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Spyre Therapeutics, Inc. is a mid-cap company with a market capitalization of $9.16B. It ranks number 35 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast.
For SYRE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.6%, sell < -0.3%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-09 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SYRE included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
| Metric | SYRE | Rank |
|---|---|---|
| Market Cap | $9.16B | 35/60 |
| P/B Ratio | 8.71x | 16/42 |
| EPS | $-2.19 | – |
| Book Value/Share | $11.93 | – |
| Metric | SYRE | Rank |
|---|---|---|
| ROE | -25.1% | 30/39 |
| ROA | -24.0% | 35/43 |
| ROIC | -23.6% | 34/44 |
| Tax Rate | 0.0% | – |
| Metric | SYRE | Rank |
|---|---|---|
| Current Ratio | 27.40x | 5/58 |
| D/E Ratio | 0.05x | 42/47 |
| Financial Leverage | 1.05x | 42/47 |
| Working Capital | $1.06B | 25/58 |
| Metric | SYRE | Rank |
|---|---|---|
| Operating Cash Flow | -$249M | 48/59 |
| Metric | SYRE | Rank |
|---|---|---|
| Operating Income | -$250M | 39/50 |
| Net Income | -$264M | 36/47 |
| R&D Expense | $260M | 42/58 |
| Metric | SYRE | Rank |
|---|---|---|
| Shares Outstanding | 88M | – |
| Total Current Assets | $1.10B | |
| Cash & Short-term Investments | $83M | 7.5% of assets |
| Total Liabilities | $48M | 4.4% of assets |
Companies classified under the same SEC industry code as Spyre Therapeutics, Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| SYRE Spyre Therapeutics, Inc. | $9.16B | |
| LLY Eli Lilly & Co | $1.33T | |
| JNJ Johnson & Johnson | $679.13B | |
| ABBV Abbvie Inc. | $518.30B | |
| MRK Merck & Co., Inc. | $367.02B | |
| NVS Novartis Ag | $312.35B | |
| AZN Astrazeneca Plc | $293.55B | |
| ABT Abbott Laboratories | $192.16B | |
| NVO Novo Nordisk A S | $183.89B | |
| PFE Pfizer Inc | $167.51B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $138.67B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $115.97B | |
| GSK Gsk Plc | $103.98B | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | |
| TAK Takeda Pharmaceutical Co Ltd | $65.66B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | |
| ONC Beone Medicines Ltd. | $47.44B | |
| GMAB Genmab A/S | $35.90B | |
| ZTS Zoetis Inc. | $32.81B | |
| RPRX Royalty Pharma Plc | $28.82B | |
| ROIV Roivant Sciences Ltd. | $28.08B | |
| INSM Insmed Inc | $25.47B | |
| UTHR United Therapeutics Corp | $24.11B | |
| VTRS Viatris Inc | $22.87B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.98B | |
| ASND Ascendis Pharma A/S | $17.07B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.81B | |
| BBIO Bridgebio Pharma, Inc. | $15.18B | |
| ELAN Elanco Animal Health Inc | $13.41B | |
| SMMT Summit Therapeutics Inc. | $13.03B | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | |
| BMRN Biomarin Pharmaceutical Inc | $11.07B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $10.00B | |
| TGTX Tg Therapeutics, Inc. | $9.49B | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | |
| CORT Corcept Therapeutics Inc | $8.11B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.76B | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | |
| ALKS Alkermes Plc. | $7.75B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | |
| CYTK Cytokinetics Inc | $7.67B | |
| AXSM Axsome Therapeutics, Inc. | $7.02B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $6.96B | |
| ORKA Oruka Therapeutics, Inc. | $6.92B | |
| ABVX Abivax S.A. | $6.83B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.80B | |
| LGND Ligand Pharmaceuticals Inc | $6.28B | |
| BLTE Belite Bio, Inc | $6.20B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.05B | |
| MANE Veradermics, Inc | $6.01B | |
| COGT Cogent Biosciences, Inc. | $5.82B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | |
| ERAS Erasca, Inc. | $5.46B | |
| EWTX Edgewise Therapeutics, Inc. | $5.29B | |
| IONS Ionis Pharmaceuticals Inc | $5.15B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $5.03B | |
| LEGN Legend Biotech Corp | $4.49B | |
| TVTX Travere Therapeutics, Inc. | $4.44B |
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by ...
I am Sam Semenkow. I'm one of the senior biotech analysts here at Citi, and it is my pleasure to be hosting Spyre Therapeutics at Citi's 2026 Biopharma Back To School Summit. I'm joined by Cameron ...
Okay. We'll continue with the next session. I'm Paul Choi, and I cover the mid-cap biotech sector here at the firm. It's my pleasure to have Spyre Therapeutics here and Cameron to my left. Maybe what ...
Our AI scores Spyre Therapeutics, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For SYRE, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -9.0%, measured on 358 forecast dates between 2022-08-22 and 2026-08-11 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 401 forecast dates between 2022-08-22 and 2026-10-09. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Spyre Therapeutics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 9, 2026.
60 issuers in our coverage, SYRE included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
